Fig. 4.

JADAS-71 over time for sJIA and pJIA patients treated with s.c.-TCZ

Data are shown as median (IQR) valuesData points at weeks 4 and 8 for the <30kg group (left-hand sJIA panel) include only those for patients receiving Q10D dosing. Horizontal dashed lines represent inactive disease (JADAS-71 < 1.0), low disease activity (≤3.8), moderate disease activity (3.9–10.5) and high disease activity (>10.5). BW: body weight; IQR: interquartile range; JADAS-71: Juvenile Arthritis DAS including 71 joints; pJIA: polyarticular JIA; Q10D: every 10 days; QW: every week; Q2W: every 2 weeks; Q3W: every 3 weeks; s.c.-TCZ: subcutaneous tocilizumab; sJIA: systemic JIA; TCZ: tocilizumab.